Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Biotech
Immutep's LAG-3 agent posts 'impressive' survival data
Immutep suggests that a high unmet need for first-line, PD-L1-negative HNSCC could potentially pave eftilagimod a path to approval.
Angus Liu
May 5, 2025 10:37am
Lilly's oral SERD Ember counts on Verzenio to broaden its glow
Dec 11, 2024 8:15am
Vir keeps pressure on Gilead with midphase hepatitis D data
Jun 5, 2024 8:52am
Gilead-Arcus' TIGIT gets high response in gastric cancer
Nov 7, 2023 9:40am
Faron's latest snapshot suggests antibody has leukemia potential
Jul 19, 2023 8:45am
HaemaLogix's myeloma drug boosts responses in Revlimid combo
Jun 29, 2023 9:10am
